Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Sep 22;13:250. doi: 10.1186/s12974-016-0715-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2016

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 5 — Teriflunomide leads to a decreased expression of CD86 in cultured microglia. Isolated microglia were treated with LPS (100 ng/ml) and different concentrations of teriflunomide (0.25–5 μM) for 48 or 72 h. a, b The histograms represent the CD86 expression levels on the microglial surface (filled: unstimulated cells; solid line: LPS-treated cells; dotted line: LPS-treated cells with 5 μM teriflunomide). c, d The mean fluorescence intensities obtained were normalized to LPS-stimulated control (black column). For comparison of the untreated (0 μM) and teriflunomide-treated samples (0.25–5 μM), a t test against the expected mean of one was used (n = 4–5). P values <0.05 were considered significant. Asterisks denote a significant difference versus the LPS-stimulated control (*p < 0.05)